Ambiru S, Miyazaki M, Isono T, Ito H, Nakagawa K, Shimizu H, Kusashio K, Furuya S, Nakajima N
First Department of Surgery, Chiba University School of Medicine, Japan.
Dis Colon Rectum. 1999 May;42(5):632-9. doi: 10.1007/BF02234142.
Hepatic resection affords the best hope of survival for patients with colorectal carcinoma metastatic to the liver. However, recurrences are observed in about 60 percent of patients after curative hepatic resection. The purpose of this study was to examine the prognostic factors of patients undergoing curative hepatic resection for colorectal metastases.
Between April 1984 and September 1997, 168 patients underwent curative hepatic resection for colorectal metastases. The clinicopathologic factors studied for prognostic value were gender, age, primary site, nodal status of primary tumor, time of metastases, preoperative serum level of carcinoembryonic antigen, hepatic tumor size and distribution, number of metastases, type of hepatic resection, resection margin, presence of micrometastases in resected specimen and microscopic fibrous pseudocapsule between the hepatic tumor and surrounding hepatic parenchyma, nodal status of hepatoduodenal ligament, adjuvant regional chemotherapy, and perioperative transfusion.
The overall survival was 42 percent at three years and 26 percent at five years, including a 3.5 percent 60-day surgical mortality rate. Thirty-one percent of patients had micrometastases located at a median distance of 3 mm from the metastatic tumor edge. Presence of microscopic fibrous pseudocapsule was observed in 28 percent of patients. Univariate and multivariate analyses showed that significant prognostic factors for survival were nodal status of primary tumor, number of metastases, resection margin, microscopic fibrous pseudocapsule, and adjuvant regional chemotherapy.
We conclude that 1) hepatic resection is effective in select patients with colorectal metastases; 2) adequate resection margin and adjuvant regional chemotherapy can improve outcome; and 3) microscopic fibrous pseudocapsule may offer additional postoperative information as an independent prognostic factor.
肝切除为结直肠癌肝转移患者提供了最佳的生存希望。然而,在根治性肝切除术后,约60%的患者会出现复发。本研究的目的是探讨接受根治性肝切除治疗结直肠癌肝转移患者的预后因素。
1984年4月至1997年9月期间,168例患者接受了根治性肝切除治疗结直肠癌肝转移。研究其预后价值的临床病理因素包括性别、年龄、原发部位、原发肿瘤的淋巴结状态、转移时间、术前血清癌胚抗原水平、肝肿瘤大小和分布、转移灶数量、肝切除类型、切缘、切除标本中微转移灶的存在以及肝肿瘤与周围肝实质之间的微观纤维性假包膜、肝十二指肠韧带的淋巴结状态、辅助区域化疗和围手术期输血。
三年总生存率为42%,五年总生存率为26%,包括3.5%的60天手术死亡率。31%的患者存在微转移灶,距转移瘤边缘的中位距离为3mm。28%的患者观察到微观纤维性假包膜。单因素和多因素分析表明,生存的显著预后因素是原发肿瘤的淋巴结状态、转移灶数量、切缘、微观纤维性假包膜和辅助区域化疗。
我们得出以下结论:1)肝切除对部分结直肠癌肝转移患者有效;2)足够的切缘和辅助区域化疗可改善预后;3)微观纤维性假包膜作为独立的预后因素可能提供额外的术后信息。